Beam Therapeutics

Biotech & Life Sciences · Cambridge, United States · Founded 2017 · IPO 2020

developing precision genetic medicines for serious diseases

Valuation $1.66B

Revenue $79M

Power Law Unicorn$1–10B valuation tier Thoroughbred$100M+ revenue

Investors

10 investors on Beam Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 10 investors entered at this stage

Cormorant Asset Management

Altitude Life Science Ventures

F-Prime

Harvard University

Omega Funds

Dreamers

Redmile Group

DHVC

ARCH Venture Partners

Eight Roads Ventures

Beam Therapeutics mafia

Startups founded by Beam Therapeutics alumni

Former Beam Therapeutics employees who went on to start their own companies. Sorted by Dealroom signal score.

PairwiseEst. 2017

David LiuUnited States

Signal score77

Prime MedicineEst. 2019

DLDavid R. LiuUnited States

Signal score64

Verve TherapeuticsEst. 2018

Keith JoungUnited States

Signal score64

Orbital TherapeuticsEst. 2022

GCGiuseppe CiaramellaUnited States

Signal score62

Book a demo to explore the full alumni network →

Global footprint

Where Beam Therapeutics has talent and traffic

Workforce by country

3 countries with
team presence

🇺🇸 United States99.5%

🇵🇹 Portugal0.2%

🏳️ Liechtenstein0.2%

3 countries shown

Web traffic by country

53K monthly visits
across markets

🇺🇸 United States61.5%

🇮🇳 India10.2%

🇨🇦 Canada5.7%

🏳️ Korea5.7%

🏳️ Republic of4.5%

Top 5 markets shown

Talent graph

The shape of Beam Therapeutics's talent

Dealroom maps Beam Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

9 standout operatorsDealroom-flagged across the org

5 AI specialistsincl. 1 core researchers

600 employees mappedperson by person

DimensionScore

AI Talentlive

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock Beam Therapeutics's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$23M patent portfolio · 90 active families

Estimated portfolio value

$23M

1.4% of market cap · 7.2× smaller than top peer Lexicon Pharmaceuticals ($166M)

90 active patent families

Where Beam Therapeutics innovates Cell biologyNucleic acidAdenosine deaminaseBase JBioinformatics

Where Beam Therapeutics concentrates vs peers

Each axis is a top-10 topic across Beam Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Beam Therapeutics

An AI-synthesized read of the highest-engagement posts about Beam Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Beam Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles